All In Biotech

Drug Trial Radar · NCT01360632

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial

Last checked: Nov 20, 2026Latest source record: Jan 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,539 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,539

Actual

Start

Jun 2011

Primary completion

Aug 2013

Study completion Sep 2013

Sponsor

Sponsor type
Industry
First posted
May 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT

Conditions

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Interventions

  • OPC-34712 + ADTDrug

    Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)

  • Placebo + ADTDrug

    Placebo + FDA Approved Antidepressant (ADT)

  • Placebo + ADTDrug

    Placebo + FDA Approved Antidepressant (ADT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample SetTime frame: Baseline and Week 14
  2. Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final ProtocolTime frame: Baseline and Week 14

Locations

71 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Costa Mesa, California

  • Research Site

    Glendale, California

  • Research Site

    Orange, California

  • Research Site

    San Diego, California

  • Research Site

    Temecula, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville Beach, Florida

  • Research Site

    Miami Springs, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Smyrna, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Oak Brook, Illinois

  • Research Site

    Lafayette, Indiana

  • Research Site

    Owensboro, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Haverhill, Massachusetts

  • Research Site

    Weymouth, Massachusetts

  • Research Site

    Rochester Hills, Michigan

  • Research Site

    Creve Coeur, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Cherry Hill, New Jersey

  • Research Site

    Toms River, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    Fresh Meadows, New York

  • Research Site

    New York, New York

  • Research Site

    Staten Island, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Beachwood, Ohio

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Portland, Oregon

  • Site not named

    Salem, Oregon

  • Research Site

    Norristown, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Lincoln, Rhode Island

  • Research Site

    Columbia, South Carolina

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.